Outlook on the Nutraceuticals Sector for 2024-2025
We sought insights from industry experts deeply versed in marketplace dynamics to discuss significant trends and developments in business, regulation, science, and the market that the industry should focus on in the upcoming year. Their insights span a range of issues, highlighting common themes such as state regulations, global supply chain strategies, and women’s health.
Michael McGuffin, President of the American Herbal Products Association (AHPA), noted that 2024 brought considerable external pressures on the industry from both state and federal critics who often confuse lawful, safe dietary supplements with illegal products. He emphasized the importance of industry unity to capitalize on the opportunities the new political landscape offers, particularly in distinguishing dietary supplements from other products. AHPA is advocating for legislative changes to enhance the FDA’s ability to crack down on illicit products disguised as supplements, thereby protecting consumers and the industry’s integrity.
Duffy MacKay, Senior VP of Dietary Supplements at the Consumer Healthcare Products Association (CHPA), reflected on the FDA’s ongoing concerns about supplements with hidden or misleading ingredients, often marketed for weight loss, sexual enhancement, and bodybuilding. He recounted significant legal actions and regulatory responses over the past years that have shaped current industry practices, including the controversial move towards “regulation by retail.”
Steve Mister, President and CEO of the Council for Responsible Nutrition (CRN), discussed the Dietary Supplement Health and Education Act (DSHEA), which has been pivotal for the industry since its inception nearly 30 years ago. He argued against sweeping reforms, advocating instead for targeted adjustments to enhance FDA enforcement and align regulations with market growth, ensuring consumer access to safe products.
Karen Howard, CEO and Executive Director of the Organic & Natural Health Association, highlighted the organization’s focus on integrity, access, and innovation in regulatory, business, and scientific domains. She detailed efforts to improve product testing and transparency, particularly concerning products derived using synthetic biology.
Loren Israelsen, President of the United Natural Products Alliance (UNPA), compared the transformative potential of recent political changes to those of 1994, emphasizing the industry’s need to engage proactively with the new administration to address longstanding regulatory challenges.
Jim Emme, CEO of NOW Health Group, reported strong growth in 2024, driven by improved supply chain dynamics and stable ingredient costs, despite ongoing challenges with transportation expenses.
Karen E. Todd, Vice President of Global Brand Marketing at Kyowa Hakko USA, discussed the shift in consumer preferences towards scientifically validated branded ingredients, noting that today’s consumers demand transparency and efficacy, influencing the market towards high-quality, research-backed products.
Shaheen Majeed, Global CEO & Managing Director of Sabinsa Corporation, touched on the complexities of pesticide testing in global markets and the importance of diversity in clinical research to address regional health needs effectively.
Elan Sudberg, CEO of Alkemist Labs, criticized recent changes in supplement seller requirements on Amazon, arguing that they impose unnecessary burdens on the industry without effectively enhancing product quality.
These insights collectively underscore a year of significant challenges and opportunities, with a strong emphasis on regulatory clarity, consumer safety, and proactive industry engagement to navigate the evolving landscape.